<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383044</url>
  </required_header>
  <id_info>
    <org_study_id>Carvedilol</org_study_id>
    <nct_id>NCT01383044</nct_id>
  </id_info>
  <brief_title>Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding</brief_title>
  <official_title>Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>E-DA Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic variceal ligation (EVL) and carvedilol have been documented to be effective in&#xD;
      prophylaxis of the first bleeding. The efficacy &amp; safety of combining EVL and carvedilol in&#xD;
      prophylaxis of the first bleeding is still unknown. This study aims to investigate the value&#xD;
      of combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination of EVL and β-blocker has been proven effective in the prevention of variceal&#xD;
      rebleeding . However, Our previous study showed that combination of EVL and nadolol do not&#xD;
      have enhanced effect in the prophylaxis of 1st variceal bleeding as compared with nadolol&#xD;
      alone . One of the drawbacks of EVL is esophageal ulcer. On the other hand ,carvedilol, an&#xD;
      anti-α beta-blocker, has been proven to be more effective than propranolol in the reduction&#xD;
      of portal pressure. Carvedilol has been proven to be more effective than EVL in the&#xD;
      prevention of 1st variceal bleeding. The investigators thus conduct a multicenter trial to&#xD;
      evaluate whether combination of EVL and carvedilol could be more effective than carvedilol&#xD;
      alone in the prophylaxis of 1st esophageal variceal bleeding . The goal of patients receiving&#xD;
      EVL is to reduce variceal size, not variceal obliteration, in anticipation for fewer sessions&#xD;
      required for each patient and fewer possibility of esophageal ulcer bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">July 8, 2011</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patients with first bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>the difference of bleeding episode in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients with complications and mortality rates</measure>
    <time_frame>3 years</time_frame>
    <description>the difference of complications &amp; survival curve between both groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Variceal Bleeding</condition>
  <arm_group>
    <arm_group_label>EVL + carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carvedilol 6.25-12.5 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EVL + carvedilol</intervention_name>
    <description>EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day</description>
    <arm_group_label>EVL + carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>carvedilol 6.25mg-12.5 mg per day</description>
    <arm_group_label>carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cirrhosis with esophageal varices are larger than F2.&#xD;
&#xD;
          2. No history of variceal bleeding.&#xD;
&#xD;
          3. In three months have not implemented preventive esophageal variceal ligation. (4)age&#xD;
             20yrs～75yrs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Association with HCC or other cancers .&#xD;
&#xD;
          2. Refractory ascites.&#xD;
&#xD;
          3. Jaundice, bilirubin &gt; 5mg/dl.&#xD;
&#xD;
          4. Encephalopathy.&#xD;
&#xD;
          5. Cr.&gt;3mg/dL.&#xD;
&#xD;
          6. A-V,block bradycardia (PR &lt; 60/mim).&#xD;
&#xD;
          7. Hypotension systolic blood pressure&lt;95/mmHg .&#xD;
&#xD;
          8. Refusal to participate.&#xD;
&#xD;
          9. Carvedilol allergy&#xD;
&#xD;
         10. Second degree-third degree Atrio-ventricular block.&#xD;
&#xD;
         11. Bradycardia.&#xD;
&#xD;
         12. WPWsyndrome&#xD;
&#xD;
         13. Hypotension&#xD;
&#xD;
         14. Psychogenic shock.&#xD;
&#xD;
         15. Asthma. All the patients are randomized based on a random number.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>E-DA hospital</name>
      <address>
        <city>Kaogsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <name_title>IRB</name_title>
    <organization>E-DA Hospital</organization>
  </responsible_party>
  <keyword>Carvedilol</keyword>
  <keyword>Banding ligation with Carvedilol</keyword>
  <keyword>the efficacy &amp; safety of combining EVL and carvedilol in prevention of first variceal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

